SCOPUS 정보 검색 플랫폼

New England Journal of Medicine

Volumn 366, Issue 9, 2012, Pages 844-846

Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms

(1) Tefferi, Ayalew a

a MAYO CLINIC (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; JANUS KINASE 2; JANUS KINASE INHIBITOR; RUXOLITINIB; STAT PROTEIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; CHRONIC MYELOID LEUKEMIA; DRUG MECHANISM; EDITORIAL; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MYELOFIBROSIS; MYELOPROLIFERATIVE CANCER; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PRIORITY JOURNAL; RELAPSE;

EID: 84857828112 PISSN: 00284793 EISSN: 15334406 Source Type: Journal
DOI: 10.1056/NEJMe1115119 Document Type: Editorial

Times cited : (55)

References (10)

1
- 17844383458
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
- DOI 10.1038/nature03546
- James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8. (Pubitemid 40663494)
- (2005) Nature , vol.434 , Issue.7037 , pp. 1144-1148
- James, C.¹ Ugo, V.² Le, C.J.-P.³ Staerk, J.⁴ Delhommeau, F.⁵ Lacout, C.⁶ Garcon, L.⁷ Raslova, H.⁸ Berger, R.⁹ Bennaceur-Griscelli, A.¹⁰ Villeval, J.L.¹¹ Constantinescu, S.N.¹² Casadevall, N.¹³ Vainchenker, W.¹⁴

2
- 77954581139
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
- Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-38.
- (2010) Leukemia , vol.24 , pp. 1128-1138
- Tefferi, A.¹

3
- 84857837774
- JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
- Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98.
- (2012) N Engl J Med , vol.366 , pp. 787-798
- Harrison, C.¹ Kiladjian, J.-J.² Al-Ali, H.K.³

4
- 84863393110
- A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
- Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807.
- (2012) N Engl J Med , vol.366 , pp. 799-807
- Verstovsek, S.¹ Mesa, R.A.² Gotlib, J.³

5
- 77956696835
- Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
- Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27.
- (2010) N Engl J Med , vol.363 , pp. 1117-1127
- Verstovsek, S.¹ Kantarjian, H.² Mesa, R.A.³

6
- 80054028202
- Long-term outcome of treatment with ruxolitinib in myelofibrosis
- Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011; 365:1455-7.
- (2011) N Engl J Med , vol.365 , pp. 1455-1457
- Tefferi, A.¹ Litzow, M.R.² Pardanani, A.³

7
- 66249137734
- Mutation in TET2 in myeloid cancers
- Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-301.
- (2009) N Engl J Med , vol.360 , pp. 2289-2301
- Delhommeau, F.¹ Dupont, S.² Della Valle, V.³

8
- 79954433836
- Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study
- Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356-63.
- (2011) J Clin Oncol , vol.29 , pp. 1356-1363
- Tefferi, A.¹ Vaidya, R.² Caramazza, D.³ Finke, C.⁴ Lasho, T.⁵ Pardanani, A.⁶

9
- 79952333359
- Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
- Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789-96.
- (2011) J Clin Oncol , vol.29 , pp. 789-796
- Pardanani, A.¹ Gotlib, J.R.² Jamieson, C.³

10
- 84855656900
- One thousand patients with primary myelofibrosis: The Mayo Clinic experience
- Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc 2012;87:25-33.
- (2012) Mayo Clin Proc , vol.87 , pp. 25-33
- Tefferi, A.¹ Lasho, T.L.² Jimma, T.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.